LGC Clinical Diagnostics and AccuGenomics partner to enhance cancer testing accuracy and drive better patient outcomes

Collaboration aims to advance precision diagnostics with enhanced NGS quality control solutions, improving reliability in cancer detection and personalized medicine.

London, UK and Wilmington, NC – September 2024 – LGC, a global leader in clinical diagnostics and genomics, announces a new strategic partnership with AccuGenomics, a pioneer in molecular diagnostic development. This collaboration is set to drive innovation in clinical diagnostic tools by combining LGC’s expertise in quality control solutions with AccuGenomics’ advanced next- generation sequencing (NGS) monitoring technologies.

This partnership will focus on developing highly accurate and reliable molecular diagnostics and quality control materials, meeting the critical needs of precision medicine and improving patient management. Through this collaboration, both companies aim to deliver enhanced solutions for cancer NGS testing quality control. LGC’s extensive clinical genomics reference material expertise, coupled with AccuGenomics’ proprietary technology, will enable laboratories worldwide to integrate third party controls into their procedures helping to ensure more reliable, actionable patient results from NGS-based assays.

“We are delighted to partner with AccuGenomics to further our mission of providing laboratories with cutting-edge quality control solutions,” said Bharathi Anekella, Executive Vice President LGC. “This collaboration aligns perfectly with our vision of advancing global diagnostics and supporting healthcare providers with the tools they need to deliver better patient outcomes.”

Nick Lazaridis, President of AccuGenomics commented “This partnership with LGC will expand the reach of our proprietary technologies and enable more laboratories to improve the reliability of their patient testing by NGS. LGC is well aligned across the diagnostic, therapeutic and pharmaceutical sectors as a strategic distribution partner. Our focus is on improving the accuracy and sensitivity of challenging NGS applications like liquid biopsy detection for MRD; this partnership with LGC will accelerate the adoption of Accukit ctDNA MRD IS, and Accukit Myeloid DNA IS. Together, we can contribute to the development of more precise life-saving diagnostic tools that support personalized medicine, leading to more accurate clinical NGS tests.”

In addition, the partnership will also focus on developing custom reference materials for NGS assay validation, supporting the evolving landscape of precision diagnostics. Both companies expect that this collaboration will accelerate the adoption of NGS technologies in clinical laboratories globally. Financial terms for this co-development agreement were not disclosed.

About LGC Clinical Diagnostics
LGC Clinical Diagnostics, part of the LGC Group, has over 30 years of experience as a leading and trusted global IVD quality manufacturer, with expertise in quality measurement tools (QMT) and reagents. Focused on five key areas – clinical biochemistry and immunoassay, serology, molecular diagnostics, clinical genomics, and reagents – it has around 450 employees across its three FDA-registered and ISO 13485-certified facilities in the USA, England and Ireland, and an ISO 9001-certified facility in England.

LGC Clinical Diagnostics partners with IVD and biopharmaceutical developers, CROs and academic institutions covering the entire diagnostic pipeline, from concept and early-stage research to accelerated product development and, ultimately, routine clinical use. It develops and manufactures a comprehensive portfolio of premium catalogue and custom-developed diagnostic quality solutions and component materials for the IVD and extended life sciences industry through its four brands, Maine Standards Company, SeraCare, The Native Antigen Company and Technopath Clinical Diagnostics. Together, they serve 7,500+ customers in over 120 countries, providing products for more than 20 clinical application areas, including infectious diseases, NIPT, diabetes, cardiac disease and oncology.

About AccuGenomics
AccuGenomics is driven to improve the accuracy and performance of NGS tests for better patient outcomes, with a focus on improving NGS technologies for the detection of cancer and infectious diseases. AccuGenomics is actively developing test solutions that enable test developers and laboratories to demonstrate the highest performance levels of their NGS assay. The company’s patented SNAQ™-SEQ technology enhances the sensitivity and specificity of NGS assays to support the advancement of precision medicine and treatment monitoring.

For more information, please visit LGC Clinical Diagnostics and AccuGenomics.

Contact Information:
Andrew Anfora
Product Management
Associate Director, Clinical Genomics
Phone: (508) 244-6400
Email: andrew.anfora@lgcgroup.com

AccuGenomics Public Relations & Business Development
Phone: (609) 491-0489
Email: ddilks@accugenomics.com